Vertex Pharmaceuticals (NasdaqGS:VRTX) FY Conference May 29, 2026 09:00 AM ET After we get through those three, the next big thing on our minds is our renal franchise. That franchise looks to have four potential medicines, starting with something called povetacicept in a disease called IgA nephropathy. It's a rare disease, but it's a common rare disease with about 150,000 people in the Western world. Beyond launching these medicines, setting up that fourth vertical, which I'm sure we'll get back to, I think ...